Quest Diagnostics updates 2025 guidance, shares trade near record valuation levels

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-24, 12:01.

Quest Diagnostics (US74834L1008) fine-tuned its full-year 2025 earnings guidance after reporting first-quarter 2026 numbers that modestly beat consensus, and the shares continue to trade on the NYSE in a range supported by steady demand for diagnostic testing services. The company now targets adjusted earnings per share between roughly 9.00 and 9.30 dollars for 2025 according to recent guidance commentary, compared with prior indications around the lower end of that band.

What the latest guidance shows

According to MarketBeat’s earnings overview, Quest Diagnostics reported first-quarter 2026 adjusted EPS of 2.50 dollars, topping the consensus estimate of 2.37 dollars by 0.13 dollars and prompting an update to its 2025 guidance range. The same data set indicates the company now expects full-year 2025 EPS around 9 dollars at the midpoint, highlighting management’s view of resilient volume trends in its core lab-testing business despite pricing pressure in some segments.

Valuation data compiled by TradingKey put Quest Diagnostics’ recent share price at about 197.15 dollars as of the close on June 23, 2026, implying a trailing price-earnings multiple near 21.4. That P/E level stands roughly 24 percent above the recent low around 16.2 and about 11 percent below the recent high just under 24, suggesting the stock trades at a moderate premium versus its own recent history while still below peak multiples.

How analysts and peers frame the stock

On the analyst side, consensus data collected by MarketBeat describe a mixed but constructive view, with several major houses rating Quest Diagnostics at Hold or Buy and an average price target that sits modestly above the current NYSE trading level. The same source notes that the updated 2025 guidance follows a period of earnings outperformance relative to expectations, which tends to support cautious optimism among covering analysts.

Peer comparison also matters for diagnostics investors, and MarketBeat’s sector pages highlight Labcorp as a key US-listed comparator in the medical laboratories and testing space. Both groups operate large reference-lab networks across the United States, and Quest Diagnostics’ valuation multiple in the low-20s on trailing earnings places it broadly in line with the sector’s mid-range for established, cash-generative diagnostic service providers.

How Quest Diagnostics earns its money

Quest Diagnostics generates most of its revenue by providing diagnostic information services, including routine blood tests, advanced clinical testing, and anatomic pathology services for physicians, hospitals and health plans across the United States. The company also operates specialized testing for oncology, cardiovascular disease and infectious diseases, and it has expanded into wellness and risk-assessment services for employers and insurers, creating a broad-based diagnostics platform that leverages its national laboratory network.

Where the shares trade today

The Quest Diagnostics shares (US74834L1008) last closed on the NYSE at approximately 196.92 dollars on 2026-06-23, 16:00 Eastern Time, with an after-hours indication around 197.18 dollars according to MarketBeat and TradingKey data.

Disclaimer: This article provides factual information and analysis and does not contain investment advice or any recommendation to buy or sell securities.